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Abstract 
The European NCI compounds programme, a joint initiative of the EORTC Research Branch, 
Cancer Research Campaign and the US National Cancer Institute, was initiated in 1993. The 
objective was to help the NCI in reducing the backlog of in vivo testing of potential 
anticancer compounds, synthesised in Europe that emerged from the NCI in vitro 60-cell 
screen. 
 
Over a period of more than twenty years the EORTC - Cancer Research Campaign panel 
reviewed approximately 2,000 compounds of which 95 were selected for further evaluation. 
Selected compounds were stepwise developed with clear go/no go decision points using a 
pharmacologically directed programme. This approach eliminated quickly compounds with 
unsuitable pharmacological properties. A few compounds went into Phase I clinical 
evaluation. The lessons learned and many of the principles outlined in the paper can easily 
be applied to current and future drug discovery and development programmes. 
 
Changes in the review panel, restrictions regarding numbers and types of compounds tested 
in the NCI in vitro screen and the appearance of targeted agents led to the discontinuation 
of the European NCI programme in 2017 and its transformation into an academic platform of 
excellence for anticancer drug discovery and development within the EORTC-PAMM group 
This group remains open for advice and collaboration with interested parties in the field of 
cancer pharmacology.  
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Introduction 
Here we describe the evolution towards a pan-European multidisciplinary academic platform 
for anticancer drug development from an international academic collaboration between 
both sides of the Atlantic. It started in 1993 as a joint initiative of the EORTC Research 
Branch, Cancer Research Campaign (CRC, now CRUK) and the US National Cancer Institute 
(NCI). The aim was to help the NCI in reducing the backlog of potential anticancer 
compounds, which emerged from the NCI in vitro 60-cell line screen, awaiting in vivo 
evaluation. The collaboration focused on compounds synthesised in Europe showing 
interesting data in the NCI screen, hence the name: the European NCI compounds 
programme. The purpose of this paper is to critically appraise the performance of the drug 
discovery programme of the EORTC/CRUK in the context of using the experience gained over 
20 years in novel drug development. 
 
The NCI provided support for screening of novel chemicals as potential anticancer 
compounds to researchers worldwide since 1955. Until 1985, the NCI screen relied primarily 
on the survival of mice bearing the murine P388 and L1210 leukaemia models, other 
transplantable mouse solid tumour models and human tumour xenografts (HTXs) (Plowman 
et al, 1997). This approach delivered only a few clinically useful drugs; mainly for leukaemia. 
To discover novel agents and to generate new leads active against common solid tumours, 
the NCI completely altered its screening programme. An in vitro panel of 60 human tumour 
cell lines comprising a variety of tumour types was established to test the cytotoxic activity 
of agents, followed by secondary testing in HTXs for selected compounds. This screen 
became fully operational in 1990 with a capacity of 10,000 compounds per year (Boyd, 1992). 
The compounds tested were selected from more than 20,000 investigational compounds 
submitted to the screen annually, based on structural diversity and novelty, and were 
acquired from a variety of sources worldwide. Europe contributed approximately 20% of 
these compounds via the NCI Liaison Office in Brussels, which was established in 1972, to 
expedite the acquisition of compounds and to act as the liaison between the EORTC and the 
NCI (Wittes and Yoder, 1998). 
 
In spite of the expected few agents, the new screen was not sufficiently discriminatory. Up 
to 1,000 compounds per annum were selected by the NCI Biological Evaluation Committee 
(BEC) for in vivo testing in subcutaneous HTXs instead of relatively few agents. This posed a 
sizable logistical and budgetary problem for the NCI; a potentially useful new chemical entity 
could be in the queue for more than a year. To cope with this, the NCI therefore developed a 
fast and low-cost hollow fibre assay (HFA) as a preliminary in vivo screen (Hollingshead et al, 
1995; 1996). The assay does not have the drawbacks of in vitro screens: the poor predictive 
capacity for in vivo activity and lack of information on potential pharmacological properties 
that are essential to deliver sufficient drug to the target (Phillips, Bibby, and Double, 2008). 
The HFA was fully implemented in 1999 and has been shown to predict for HTX activity 
(Bijnsdorp and Peters, 2008; Johnson et al, 2001). 
 
In the intervening years, 1990-1999, there was an urgent need to develop new anticancer 
agents. Concerns on the backlog of compounds for in vivo HTX testing at the NCI in the early 
90s led the EORTC Screening and Pharmacology Group (SPG) to propose to take on some 
secondary HTX testing for the NCI. This resulted in 1993 in the initiative of the European NCI 
compounds programme and the development of a pharmacological approach by EORTC and 
CRC to select potential anticancer agents (Double, 1999). Since that time all compounds 
originating from Europe and referred to the BEC were candidates for studies in the 
programme. It should be noted that already at that time many of the HTXs available in the 
major testing laboratories of the SPG were in fact patient-derived xenografts (PDXs) and not 
HTXs derived from human tumour cell lines (Boven et al, 1992; Langdon et al 1994). The 
number of available PDXs in those laboratories has considerably increased over time. 
 
The goal was to develop the selected new chemical entities in a stepwise manner using a 
pharmacologically guided strategy, starting with pre-formulation, assay development and 
stability studies; followed by preliminary in vivo toxicology and pharmacokinetic studies as 
well as mechanism of action and additional in vitro and in vivo studies. 
 
The CRC and EORTC Research Branch set up a Review Committee of 9 and later 14 members, 
all with considerable experience in experimental therapeutics and anticancer drug 
development. They represented EORTC committees and Research Branch groups, the 
CRC/EORTC/NCI Joint Working Formulation Party, selected experts and the drug 
development offices of EORTC (NDDO, Amsterdam) and CRC (London) as well as the NCI 
Liaison Office (Table 1). In addition, the Review Committee identified and approached expert 
EORTC and CRC investigators that could be interested in working on compounds selected by 
the Review Committee. If so, they were invited to attend the Review Committee meetings. 
The review and discussions on the data of the compounds were strictly confidential and all 
involved in the evaluation and testing signed a confidentiality agreement. Table 2 shows the 
Chairs and Secretaries of the European NCI compounds programme over the years. 
 
The evaluation process of the European NCI compounds started at the NCI with the 
collection of the available data from the BEC referrals for which permission from the 
suppliers was obtained to show the data to the Review Committee. The NCI Liaison Office 
then forwarded the data to the CRC Drug Development Office who subsequently distributed 
the results to the members of the Review Committee. Each member could select up to 6 
compounds, indicate the interest in the compound on a three-point scale (borderline 
interesting, interesting or very interesting) and present the reason(s) for the selection. The 
individual evaluations were sent to the CRC Drug Development Office, which summarised 
the outcome and drafted the short list. At the next meeting of the Review Committee, the 
shortlist was discussed. The result was relayed via the NCI Liaison Office to the NCI together 
with a request for samples of the selected compounds. The NDDO was responsible for the 
distribution of the samples to EORTC and CRC investigators, and the coordination and 
collection of all experimental data. New experimental data were presented and discussed at 
the next Review Committee meeting and the decision was taken as to whether a compound 
qualified for further development, required further studies or was discontinued. 
 
The data on the compounds to be judged by the Review Committee members comprised the 
chemical structure, the dose-response curves over a 5-log concentration range (10-4–10-8 or 
10-5–10-9 M) in each of the 60 tumour cell lines after 48 hours (h) drug exposure, the mean 
graph, the COMPARE data and, if available, molecular target data from the NCI 60-cell line 
panel (Holbeck, 2004) and HFA results. Structurally related and unrelated compounds with a 
high degree of similarity in the COMPARE programme, the COMPARE-positive compounds 
(Pearson correlation coefficient ≥0.8), often showed the same mechanism of action (Grever, 
Schepartz and Chabner, 1992). COMPARE-negative compounds (Pearson correlation 
coefficient <0.8), which did not have close matches in the COMPARE programme, were 
thought to be the most interesting leads by the Review Committee, as they might have a 
novel mechanism of action. 
 
In summary, important selection criteria for the Review Committee were the novelty of the 
chemical structure, COMPARE-negativity and potency (<10-6 M) because the Review 
Committee was seeking compounds with a novel mechanism of action with the potential to 
be a clinical candidate. If enough compelling data were present analogues of existing agents 
and COMPARE-positive agents were occasionally considered. Differential growth inhibition 
and, if available, molecular target data (genes, mRNAs, proteins, enzymes), in vivo data and 
the supply of material were other criteria. The NCI required for in vitro screening a minimum 
amount of 10-15 mg from suppliers meaning that a very limited amount was available for 
the European NCI compounds programme. If the supplier was not able to provide additional 
material, the compound was not selected. Sometimes, for particularly interesting agents, the 
NCI helped by having the material manufactured by subcontractors. Figure 1 depicts the flow 
diagram of the selection and the development of selected European NCI compounds. 
 
The first decade (1993-2003) 
During the first decade of the EORTC/CRC/NCI collaboration the selected compounds were 
developed using Standard Operating Procedures (SOPs; Supplementary data, SOPs A-E). The 
European NCI compounds programme was a voluntary system of committed investigators 
using their personal budgets to test the compounds. It did not receive any financial support 
from the EORTC, but the NCI provided limited numbers of mice for quite a number of years. 
The limited resources in manpower, finances, equipment and mice had to be used as 
efficiently as possible. Only small in vitro and in vivo studies were carried out, just sufficient 
to provide enough evidence to justify the next step in the preclinical development of the 
compound or to abandon it. 
 
Because the solubility of many compounds is very challenging, the first stage of the 
pharmacological approach was pre-formulation (Table 3), followed by the development of a 
simple sensitive analytical assay, and stability and purity studies. The following steps aimed 
to determine the potential bioavailability by determination of the maximum tolerated dose 
(MTD, single dose (SD), intraperitoneal (ip)) in mice in the best pre-formulation found, 
followed by plasma pharmacokinetics at various time points using the MTD. In the case 
where the peak plasma concentrations approached the in vitro IC50 value, the compound 
was further evaluated in vitro for 1 h and 48 h against the most sensitive tumour cell line in 
the NCI panel. The 1 h exposure was to mimic in vivo bolus injection and the 48 h to confirm 
the NCI data. If the compound in the 1 h assay was active at the concentration achieved in 
the pharmacokinetic study then in vivo studies were initiated against the corresponding HTX 
(SD, ip). When the compounds were inactive in the 1 h assay but active in the 48 h assay, a 
repeat dose schedule (q1dx5) was considered. When a compound showed interesting 
activity in vivo, further in vitro studies were performed to investigate whether the 
compound had a broader activity in other tumour cell lines/tumour types than those tested 
in the NCI panel and to study the haematoxicity of the compound in bone marrow using the 
haematopoietic stem cell assay. 
 
The practical work of the Review Committee started in November 1993 with the review of 
the first set of 126 European NCI compounds. From the short-list of 31 compounds, 16 were 
selected. With more experience gained, the number of selected compounds of subsequent 
sets was reduced to 2-7 per set. 
 
To provide an idea of the efficiency of the stepwise pharmacologically guided approach, the 
history of the selected compounds from the first set is given as an example. From the 
original 126 compounds 16 were selected, from which the development of five compounds 
was already abandoned after completion of the first step (pre-formulation studies) due to 
severe solubility or stability problems and/or impurity. Another four compounds failed to 
hold the threshold of the second step, the preliminary toxicology and plasma 
pharmacokinetic studies: one compound was still found to be unstable, one compound 
showed solubility and toxicity problems and the plasma level of the MTD of two compounds 
was below the in vitro IC50 value. In the third step the efficacy of the 7 remaining compounds 
was investigated in several HTXs in vivo. Three compounds were found to be inactive in vivo, 
two compounds were dropped for low sensitivity of the analytical assay and a sixth 
compound was dropped due to lack of drug supply in combination with a low level of activity 
in several HTXs. 
 
The sixteenth compound (D643314) was from the beginning considered as the most 
interesting one of set 1. This COMPARE negative compound was selected for its potency 
(IC50<0.5 µM), differential activity in colon and ovarian cancer, and its chemical structure 
suggested to be a potential tubulin binder. It was moderately soluble in PEG 400/absolute 
ethanol/Tween 80 and readily soluble in 10% DMA/Arachis oil formulation. 
Pharmacokinetics showed a peak value at 15 minutes 60-90 fold above the IC50 and at 24 h 
its plasma level was <1 µM. Additional mechanistic studies (performed during in vivo 
evaluation) showed inhibition of tubulin assembly, substantial anti-vascular activity in vitro 
and activity against cisplatin-, doxorubicin- and taxol-resistance human ovarian tumour cell 
lines in vitro. Overall, it was considered as a possible candidate for clinical phase I study. The 
efficacy was, however, marginally or absent in the seven HTXs tested (4 ovarian, 2 colon, 1 
non-small cell lung cancer) and its was therefore concluded that were no compelling data to 
continue further development. 
 
Based on the NCI selection criteria the 126 compounds of set 1 would have been tested in 
vivo. This overview clearly shows the strength of the pharmacologically guided approach: it 
rapidly removed nine out of sixteen compounds with unsuitable pharmacological 
characteristics. Only seven compounds went into in vivo efficacy studies, thereby saving 
animals, expenses and other resources. 
 
Reports on the European NCI compounds programme have been presented in 1996 (Schultz 
et al, 1996), 1997 (Double, 1999) and 1998 (Hendriks et al, 1998). In 1998, the Review 
Committee had reviewed approximately 700 compounds and 40 were selected. Twenty of 
these compounds were dropped and the other 20 were at various stages of testing. By 2003, 
approximately 1,500 compounds had been reviewed and 77 selected. Most had been 
discontinued for reasons of solubility, instability, impurity, unavailability of material, 
insufficient bioavailability, lack of efficacy in HTX models in vivo, and other grounds. 
 
Certainly, in the beginning, the European NCI compounds programme was hampered by a 
relatively slow transfer of information (phone, airmail, fax) compared to  todaǇ’s staŶdaƌds, 
lengthy procedures in getting consent from original suppliers via NCI to share their data, 
difficulties in obtaining sufficient material, and resource limitations. This often resulted in a 
delayed start of the experiments. 
 
Nevertheless, the merit of the European NCI compounds programme is illustrated by the 
development of two compounds towards clinical trials: DRH-147 and Phortress. 
 
DRH-417 belongs to a series of pyrrolobenzodiazepine monomers, designed to fit sequence 
selectively into the minor groove of DNA. It was very potent in the NCI 60-cell line panel 
(mean IC50 3 nM) and showed differential activity against melanoma, breast and renal cell 
cancer, which was confirmed by EORTC in vitro studies.  DRH-417 went therefore to the next 
step in our pharmacological approach: investigation of its in vivo characteristics. The MTD 
was first established (0.5 mg/kg, SD ip) and plasma pharmacokinetics were determined using 
a novel selective HPLC method. Plasma pharmacokinetics showed concentrations far above 
the IC50 value.  The plasma AUC was 540 nM/h and peaked at 30 min (171 nM), which is far 
above the IC50 value. Subsequently, the antitumour activity was investigated. The 
compounds showed marked activity in vivo in two human renal cell cancer HTXs, a breast 
cancer HTX and a murine syngeneic colon cancer (p<0.01). Genomic profiling of in vivo 
sensitive HTXs demonstrated an activated insulin-like growth factor signalling pathway 
(Burger et al, 2007). The development of DRH-417 was however discontinued when SJG-136 
(also known as SG2000) showed more promising results. SJG-136 was a novel compound in 
the series of pyrrolobenzodiazepine dimers, that was simultaneously developed by CRC and 
NCI. SJG-136 is currently in phase II clinical studies in ovarian cancer and leukaemia (Mantaj, 
2016). 
 
Phortress is a water-soluble benzothiazole prodrug whose active moiety (5F 203) is liberated 
in plasma and tumour cells. 5F 203 possessed highly potent activity (low nanomolar GI50) and 
selectivity against breast and ovarian cancer sub-panels of the NCI 60-cell line screen. 5F 203 
was converted to a water soluble lysylamide prodrug to allow parenteral administration and 
avoidance of first pass metabolism in the liver, an abundant site of the drug activating 
metabolic enzyme CYP1A1. Within tumour cells Phortress is hydrolysed to 5F 203 that binds 
to cytoplasmic aryl hydrocarbon receptors (ArH). The complex is translocated into the 
cellular nucleus, where it binds to the cyp1a1 promoter, leading to an induction of the 
expression of cytochrome P450 1A1 (Figure 2). The resulting highly reactive intermediate 
species forms DNA adducts resulting in cell death. Based on its selective antitumour profile 
(breast, ovarian and renal cancers), unique mechanism of action and good pharmacokinetic 
characteristics, the safety and toxicity of Phortress was investigated in a phase I clinical trial 
in advanced cancer between 2004 and 2012 (Leong et al, 2004). Preliminary data showed 
that the compound was well tolerated and the MTD was not reached (Seckl et al, 2012). 
Thirty-three per cent of the patients (14/42) were classified as having stable disease and 
several cases of prolonged disease stabilisation were recorded including patients with renal 
cancer and mesothelioma. Despite its selective preclinical activity in breast and ovarian 
cancers, patients with these tumour types were not included in the study. 
 
The development of Phortress required investigation of several successive generations of 
benzothiazoles (Bradshaw and Westwell, 2004). The European NCI programme contributed 
by studying a number of compounds from this programme, which increased insight into their 
efficacy and mechanism of action. EORTC investigators also participated in the in vivo 
antitumour efficacy studies of Phortress (Fichtner et al, 2004). 
 
The second decade (2003-2013) and further 
Major changes occurred in the composition and support of the work of the Review 
Committee in the second decade. The NDDO discontinued its support to the Review 
Committee in 1998 as a consequence of a difference in approach in drug development 
between EORTC and the NDDO (Hanauske, 1998) while in 2007 the Drug Development Office 
of CRUK (formed by fusion of CRC and Imperial Cancer Research Fund in 2002) withdrew 
from the review process due to resource limitations and the absence of clinical candidates 
emerging from the programme. Structural changes occurred also within the EORTC Research 
Division (now Translational Research Division): the PAMM group merged with the Preclinical 
Therapeutic Models Group (2000) and the SPG (2003). The latter operates within the PAMM 
as the Drug Discovery Committee (DDC) (Peters et al, 2012). 
 
From its establishment in 1972 to 2001 the NCI Liaison Office in Brussels was the primary 
contact for the acquisition of compounds from Europe for screening by the NCI. Submission 
of novel agents to the NCI screen only became possible from 2001 through the NCI website 
of the Developmental Therapeutics programme. At the same time the NCI restricted the 
numbers of compounds to be tested annually from 10,000 to 3,000 and discontinued the 
scƌeeŶiŶg of ͞aŶalogues ƌelated to ǁell-studied dƌugs͟ such as aŶthƌacǇcliŶes, taǆaŶes, 
camptothecins and platinum-based agents. This was changed because NCI preferred to focus 
on compounds with a molecular target-based rationale. In 2003 the role of the NCI Liaison 
Office changed to promote and facilitate the mission of the NCI Center for Global Health in 
the European Region and the office closed at the end of October 2015. All these changes 
caused a steep decline in the number of European NCI compounds referrals by the BEC to 
the Review Committee: up to 2004 the median number of European NCI compounds offered 
for review was 103 per set (range 24-230, 18 sets), but reduced to 20 per set (range 6-47, 10 
sets) in the years up until 2014 with zero referrals in 2014-2016. 
 
Economic, societal and scientific developments in the second decade also affected the 
European NCI programme. Lower budgets for the laboratories of the participants and 
restrictions on the use of animal experiments reduced the number of experiments on 
compounds from the programme. This and the rising number of targeted agents 
necessitated a change in strategy and adaptations to the work and procedures of the 
European NCI compounds programme. Apart from the fact that the Review Committee was 
renamed the Joint EORTC Committee (JEC) on European NCI compounds, the stepwise 
development of compounds was abandoned in 2007 and emphasis was put on more tailored 
drug development plans after in-depth discussions with suppliers at the DDC meetings, 
which followed the JEC meetings. In addition, promising agents were further investigated in 
PAMM-DDC mini-projects, intended to support drug development with feeder money out of 
the PAMM Group income (Peters et al, 2012). 
 
Two examples of the new approach are the developments on a series of combretastatin A-4 
analogues and NSC 734237, a Paullone-like molecule. 
 
Combretastatin A-4 is a natural product, poorly soluble, and the active metabolite of the 
vascular disrupting agent combretastatin A-4 phosphate. It prevents microtubule 
polymerisation in endothelial cells of tumour blood vessels and disrupts endothelial 
junctions, causing tumour blood vessel collapse and tumour necrosis (Dark et al, 1997; Tozer 
et al, 2002). The JEC selected a couple of COMPARE-negative compounds from a series of 
novel combretastatin A-4 analogues (1,5-diaryl-1H-imidazoles), based on their high potency 
(nM-µM range) and differential selectivity in human colon, breast and renal cancer cell lines. 
In the subsequent DDC meeting, the supplier presented an overview of and the background 
on the compounds. Subsequent studies, partly as a PAMM-DDC mini-project, focused on 
three compounds (NSC736359, NSC736992, NSC733436) and their water-soluble salts. The 
results showed that the compounds disorganised microtubules, selectively affected 
endothelial cell morphology and capillary formation in vitro, and caused blood vessel 
shutdown and tumour necrosis in vivo, thus confirming their vascular disrupting properties 
(Bonezzi et al, 2009). The antitumour activity (SD, ip) against a well-vascularised breast 
cancer HTX in vivo was moderate at tolerated doses but more pronounced at toxic dose 
levels. Additional studies with the water-soluble salt of NSC736992, the most potent one of 
the series, in the same HTX confirmed that its efficacy was moderate to borderline. This was 
also observed with other treatment schedules, while the efficacy was not increased in 
combination with carboplatin or taxol. In both experiments, the density (size and number) of 
CD31+ blood vessels was not affected by the test compounds alone or in combination. 
 
The Paullone-like molecule NSC 734237 is another example and part of a series of 
isoindoloquinoxalines with IC50 values in the low and sub µM range (Diana et al, 2008). It 
showed reasonable, but inconclusive, differential activity for CNS, colon, melanoma and 
breast cancer lines in independent assays in the NCI in vitro screen. The compound was quite 
insoluble (6% active drug in a liposomal formulation). In a subsequent EORTC in vivo study it 
induced, however, dose-dependent antitumour activity in the doxorubicin-resistant, 
oestrogen receptor negative human breast cancer xenograft MT-3/ADR with significant 
activity at the MTD (ip, d8-12, 15-19). Immunohistochemistry showed a dose-dependent 
reduction in both CD31+ microvessel density and Ki-67 staining demonstrating cytotoxic 
activity and antivascular effects. The efficacy in the chemosensitive human breast cancer 
xenograft MBA-MB 453 was, however, marginal (ip, q1dx5) or inactive (ip, q7dx2). In the 
meantime results from the NCI Molecular Targets Laboratory showed inhibition of the 
topoisomerase I enzyme and inhibition of tubulin polymerisation. After consultation with the 
supplier, the IC50 profile of 13 other structures from the same series was investigated in a 
limited number of tumour cell lines in vitro. Four compounds were selected and then tested 
against the whole cell line panel at Oncotest in Freiburg: two had differential activity against 
human pancreatic cancer (1/2), non-small cell lung cancer, and melanoma tumour cell lines. 
Lack of material prevented plans to investigate whether the compound could overcome 
topoisomerase I-resistance and perhaps possess PARP inhibitory activity. In conclusion, the 
compound showed interesting activity and mechanisms of action, but solubility prevented 
further investigations. A more highly soluble analogue or a new formulation would be 
options to investigate. 
 
Lessons learned and future prospects 
Approximately 2,000 compounds were reviewed and 95 selected in more than twenty years 
of the European NCI compounds programme. Several compounds moved to early stage 
clinical development, but  no compounds progressed to late stage clinical evaluation. The 
pharmacologically directed approach demonstrated clearly that a few simple procedures 
with small numbers of mice quickly eliminated agents that were highly unlikely to have any 
antitumour activity, either because they were impure, unstable, unformulatable or had a low 
bioavailability. Existing systems would have required many more mice to produce the same 
result, which is not only important economically but also ethically. Double already proposed 
in 1999 that with adequate resourcing the process could run quite quickly and agents with 
unsuitable pharmacological properties could have been eliminated in less than three months. 
This would have represented a major overall saving in finances and animals but also in drug 
development time which would have allowed urgently needed new agents to enter clinical 
studies more rapidly (Double, 1999; Hendriks et al, 1998). This approach would nowadays 
perfectly fit within for instance the multi-tier framework proposed by the Cancer Target 
Discovery and Development Network (2016) that aims to convert "Big Data (e.g. novel 
sequencing platforms)" into pharmacologic targets, lead compounds, and biomarkers for 
rapid clinical testing. 
 
With regard to the original goal of the iŶitiatiǀe ͞to ideŶtifǇ new chemical entities with 
phaƌŵacological pƌopeƌties that ŵaǇ pƌedict geŶuiŶe cliŶical poteŶtial͟ agaiŶst solid caŶceƌs, 
limited success was achieved in cases such as the benzothiazole prodrug (Phortress) and the 
pyrrolobenzodiazepine monomer DRH-417. That is not surprising given the large attrition 
rate of novel anticancer agents (Kamb, Wee and Lengauer, 2007) and the number of 
compounds reviewed, selected and tested in the European NCI compounds programme. It is, 
however, important to realise as stated by JEC member Malcolm Stevens at the 2010 DDC 
meeting that ͞a number of anticancer drugs could not have been developed without 
knowledge gained from work on agents that did not go into or went into clinical studies but 
did not make it͟. The informal but confidential nature of the JEC was essential for this 
success as well as interactions between the various disciplines represented in the JEC. Such a 
multidisciplinary academic network of experts in preclinical anticancer drug development 
was unique in the early 1990s, even between various departments within a university, let 
alone between various universities in different European countries. Nowadays we can hardly 
imagine not collaborating in multidisciplinary teams. 
 
In the 2nd decade of the European NCI compounds programme the pharmacologically 
directed approach was partially abandoned and replaced by intensive discussions with 
suppliers on characteristics of the compounds and the way to develop them. Unfortunately, 
the engagement from the suppliers was with some exceptions low. Therefore, the JEC 
refocused its efforts to identify and collaborate with pharmaceutical chemistry-based 
academic groups. These groups share a common interest in drug discovery that would 
benefit from interactions with JEC and the PAMM-DCC. The various panels of the early HTXs 
(now called PDXs) have been characterised by genomic profiling (for instance Fiebig et al, 
2007,  Fichtner et al, 2008). These carefully built-up portfolios of PDXs (profiled for many 
standard chemotherapeutic, targeted agents and investigational agents) will further 
contribute to the development of compounds against novel molecular targets. Development 
of PDXs from ethnic subtypes (e.g. China, Japan, India) could refine the test system. In 
addition, interactions with statisticians may contribute to coping with analysis of big data in 
oncology. 
 
To summarize, the European NCI compounds programme and JEC was successful in its initial 
aims. The programme has now been superseded by other drug discovery approaches and 
therefore discontinued/terminated. However, it is important that the lessons learned from 
over 20 years of multinational and multidisciplinary collaborations are not lost and are 
applied to future drug discovery programmes. The EORTC-PAMM group (and the associated 
Drug Development Committee) nevertheless remains active and will provide a platform for 
anticancer drug discovery and development, open for advice and collaboration to academia, 
biotechnology and pharmaceutical industry partners. 
 
Conclusions 
In spite of the collaborative effort provided on a voluntary basis and very restricted budgets, 
the initial ambitious aim of the European NCI compounds initiative to develop compounds 
coming from the NCI screen toward clinical evaluation and implementation was partly 
achieved since several drugs went into Phase I clinical trials. Development of compounds 
was hampered for various reasons such as speed of experimentation, frequency of the JEC 
meetings and absence of funding. Of utmost importance, the work resulted in fruitful 
multidisciplinary interactions in Europe and increased the understanding of knowledge of 
structures and mechanism of actions of drugs that made it to the clinic. The programme 
transformed from pan-European multidisciplinary collaborations into an academic platform 
of excellence for anticancer drug discovery and development. It fosters the collaborations 
with the NCI and is open for any initiative in the field of cancer pharmacology. 
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Coordinating Committee (NDDCC) 
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Omar Yoder 1993-1999 NCI Liaison Office 
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Group 
Heiner Fiebig 1995-present Selected expert 
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David Secher 1995-2000 Director, CRC Drug Development Office 
Coen van Kalken 1995-1998 Director NDDO 
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Table 2. Overview of Chairman & Secretary CRC/EORTC Review Committee European 
NCI compounds programme 
Period Chairman Period Secretary 
1993-2000 Herbie Newell 1993-1998 Hans Hendriks 
1999 Veronica Verdon 
2000-2003 John Double 2000-present Anne-Sophie Govaerts 
2003-2006 Iduna Fichtner 
2006-2008 Angelika Burger 
2008-2011 Frits Peters 
2011-2014 Andrew Westwell 
2014-present Frits Peters (ad 
interim) 
 
  
Table 3. Formulations used in the European NCI compounds programme 
Formulations 
1. Water for injection 
2. Absolute ethanol 
3. N,N-dimethylacetamide (DMA)* 
4. 0.5% Tween 80 in 0.9% NaCl (g/v) 
5. Polyethylene glycol 400/absolute ethanol/Tween 80 (6:3:1 v/v/v) 
6. DMA/Arachis oil (1:10, v/v) 
7. Cremophor EL/absolute ethanol (1:1, v/v) 
* In view of bad experience with DMA as vehicle in studies in vivo, it was decided in 1995 to 
replace DMA by DMA/Arachis oil (1:10, v/v) 
 
  
 Figure 1 
Flow diagram of the European NCI compounds programme 
Peer Review in vitro data and, if available, in vivo data 
 
Selection criteria:  Novelty of Structure  COMPARE negative  Mean graph and curve profiles (Tumour 
specificity/differential growth inhibition)  Potency (<10-6 M)  Sample availability 
Pre-formulation and Assay Development 
Preliminary Toxicity 
(MTD, SD, ip; 2 mice/dose and solvent control) 
Reject unformulateable, impure or unstable 
agents or if no simple assay can be found 
Plasma pharmacokinetics at MTD 
- Pilot study: 2 mice /time point (15, 60 min). If plasma 
level below IC50→ stop, otherwise main study 
- Main study: 4 mice/time point (15 min, 1 h, 6 h, 24 h) 
Does bioavailability equate IC50? 
Yes:  
Short term in vitro cytotoxicity (1 h and 48 h) 
- 1 h active → In vivo HTX (q1dx1) 
- 1 h inactive → review, if active in 48 h → in vivo HTX (q1dx5) 
- Inactive 48 h → discontinue 
No: Review or reject 
26 
 
 
 
 
 
Figure 2 
Self-potentiation of Phortress. After being taken up in the cell Phortress  is converted in the cytoplasm to 5F203 that 
binds to the aryl hydrocarbon receptor. This complex is translocated to the nucleus, where it acts as a transcription 
factor by binding to the promotor of the cyp1a1 gene, leading to an increased cyp1a1 mRNA expression, resulting in 
an increased activity of the CYP1A1 enzyme that converts 5F203 into a bioreactive species that forms DNA adducts 
leading to single and double DNA strand break, resulting in cell death. 
Reproduced by kind permission of the author and Pharmaceutical-journal.com (http://www.pharmaceutical-
journal.com) from Bradshaw TD (2010) Phortress: the smart antitumour agent which induces its own metabolism 
Pharm J  284: 23-24 
 
